Telomerase activator TA-65MD® in patients with ACS (TACTIC)

• Research type

  Research Study

• Full title

  Telomerase ACTivator to reverse Immunosenescence in Acute Coronary Syndrome: a double-blind, phase II, pilot randomised controlled trial (TACTIC)

• IRAS ID

  232100

• Contact name

  Ioakim Spyridopoulos

• Contact email

  ioakim.spyridopoulos@ncl.ac.uk

• Sponsor organisation

  South Tees Hospitals NHS Foundation Trust

• Eudract number

  2017-002876-26

• Duration of Study in the UK

  2 years, 1 months, 1 days

• Research summary

  Throughout life, the length of telomeres (protective caps of chromosomes) becomes shorter and this is linked to cell ageing and a decrease in cell health. Shorter telomeres in white blood cells (specifically CD8 T cells) are associated with deterioration of the immune system and increased risk of heart attacks and other heart problems.
  There is a drug called TA-65MD® that has been shown to stimulate cells to add-back some of the lost telomeres by activating the enzyme telomerase, which is responsible for elongating and maintaining telomeres.
  The main purpose of the TACTIC study is to see whether TA-65MD® treatment for 1 year increases the length of the protective telomeres, and whether this leads to fewer ‘aged’ CD8 T cells (cells with shorter telomeres) in patients who have coronary heart disease.

• REC name

  North East - Newcastle & North Tyneside 1 Research Ethics Committee

• REC reference

  18/NE/0178

• Date of REC Opinion

  9 Aug 2018

• REC opinion

  Further Information Favourable Opinion